Zobrazeno 21 - 30
of 99
pro vyhledávání: '"Allison Berger"'
Autor:
Akito Nakamura, Stephen Grossman, Keli Song, Kristina Xega, Yuhong Zhang, Donna Cvet, Allison Berger, Gary Shapiro, Dennis Huszar
Publikováno v:
Blood. 139(18)
Small ubiquitin-like modifier (SUMO) is a member of a ubiquitin-like protein superfamily. SUMOylation is a reversible posttranslational modification that has been implicated in the regulation of various cellular processes including inflammatory respo
Autor:
Zhen Lu, Noreen McBrearty, Jinyun Chen, Vivek S. Tomar, Hongru Zhang, Gianluca De Rosa, Aiwen Tan, Aalim M. Weljie, Daniel P. Beiting, Zhen Miao, Subin S. George, Allison Berger, Gurpanna Saggu, J. Alan Diehl, Constantinos Koumenis, Serge Y. Fuchs
Publikováno v:
Cell Metabolism. 34:1342-1358.e7
Effector trogocytosis between malignant cells and tumor-specific cytotoxic T lymphocytes (CTLs) contributes to immune evasion through antigen loss on target cells and fratricide of antigen-experienced CTLs by other CTLs. The mechanisms regulating the
Autor:
Jeffrey Houlton, Harrison Cash, Haodong Xu, Paul L. Swiecicki, Keith Casper, Steven B. Chinn, Daniel R. Clayburgh, Ryan J. Li, Robert J. Christian, Aaron Halfpenny, Annemieke van Zante, Beryl A. Hatton, Kimberly Sottero, Marc O. Grenley, Connor Burns, Jason Frazier, Jonathan Derry, Gloria Kung, Emily Beirne, Nathan J. Schauer, Atticus Turner, Wendy Jenkins, Kirsten Anderson, Richard A. Klinghoffer, Dennis Huszar, Allison Berger, Karuppiah Kannan
Publikováno v:
Cancer Research. 82:CT139-CT139
Purpose/Objectives: The human tumor microenvironment (TME) has a dramatic impact on cancer prognosis and therapeutic response, but accurate models of the native TME do not exist. The Comparative In Vivo Oncology (CIVO) platform was developed as a mea
Autor:
Sharon Friedlander, Jordi Rodon, Anthony J. Olszanski, Alonzo Martinez, Ulka N. Vaishampayan, Arkadiusz Z. Dudek, Robert Gharavi, John F. Gibbs, Bo Chao, Afshin Dowlati, Christine K. Ward, Bingxia Wang, Alejandro Gomez-Pinillos, Dejan Juric, Vaishali Shinde, Hadeel Assad, Allison Berger, Igor Proscurshim
Publikováno v:
Journal for ImmunoTherapy of Cancer. 9:A505-A506
BackgroundSUMOylation is a post-translational modification that serves as an important modulator of immune responses via its role in constraining the type I interferon (IFN-1) response. TAK-981 is a small molecule that inhibits SUMOylation and increa
Autor:
Akito Nakamura, Keli Song, Stephen Grossman, Kristina Xega, Yuhong Zhang, Allison Berger, Gary Shapiro, Dennis Huszar
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background TAK-981 is a first-in-class small molecule inhibitor of the SUMO activating enzyme in Phase 1 clinical trials. SUMOylation has previously been implicated in the regulation of innate immune responses and expression of Type I interferons,1 a
Autor:
Maria Patra-Kneuer, Stefan Steidl, Akito Nakamura, Andrea Polzer, Stephen Grossman, Igor Proscurshim, Carmen Ginzel, Keli Song, Christina Heitmüller, Allison Berger
Publikováno v:
Blood. 138:2268-2268
Introduction TAK-981 is a first-in-class small molecule inhibitor of the SUMO activating enzyme currently in Phase I/II clinical trials. TAK-981 has been shown to increase NK cell activation and M1 macrophage polarization via upregulation of Type I i
Autor:
Lili Wang, Xiaoguang Wang, Tanya Siddiqi, Allison Berger, Alexey V. Danilov, Dan Vuong, Vi Lam, Olga V. Danilova, Tingting Liu
Publikováno v:
Blood. 138:2414-2414
Introduction: Immune checkpoint inhibitors have limited single agent activity in B-cell non-Hodgkin lymphoma (NHL). Hence, it is important to develop strategies which will thwart immune evasion in this disease. Neddylation is a sequential enzyme-base
Autor:
Shaji Kumar, Jeremy T. Larsen, Saulius Girnius, Rafat Abonour, Igor Proscurshim, Omar Nadeem, Akito Nakamura, Yuhong Zhang, Keli Song, Stefano R. Tarantolo, Vivek Roy, Meera Mohan, Moshe Yair Levy, Allison Berger, Deborah Berg, Cara A. Rosenbaum, Sagar Lonial, Ralph V. Boccia, Habte A. Yimer, Bo Chao, Christine K. Ward
Publikováno v:
Blood. 138:2742-2742
Background: SUMOylation, a post-translational modification analogous to ubiquitination, attaches a small, ubiquitin-like modifier (SUMO) to target proteins. SUMOylation plays a central role in the immune system by regulating type I interferon (IFN-I)
Autor:
Alejandro Gomez-Pinillos, Alonzo Martinez, Allison Berger, Amitkumar Mehta, Deborah Berg, Stephane Doucet, Paolo Caimi, Tycel Phillips, Lapo Alinari, Brenda W. Cooper, Bo Chao, Christine K. Ward, Igor Proscurshim, John Gibbs, Sarit Assouline, Alexey V. Danilov, Sharon Friedlander, Steven I. Park
Publikováno v:
Blood. 138:2488-2488
Background: TAK-981 is the first small-molecule inhibitor of SUMOylation to enter clinical trials. SUMOylation is a post-translational modification in which small ubiquitin-like modifier (SUMO) proteins are activated and covalently attached to substr
Autor:
Evan F. Lind, Vi Lam, Nathan D. Pennock, Scott R Best, Adam Kittai, Alexey V. Danilov, Nur Bruss, Allison Berger, Susan E. Murray, Tingting Liu, Olga V. Danilova
Publikováno v:
Leukemia
Novel targeted agents used in therapy of lymphoid malignancies, such as inhibitors of B-cell receptor-associated kinases, are recognized to have complex immune-mediated effects. NEDD8-activating enzyme (NAE) has been identified as a tractable target
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcae410fe576a9e2b7a646012b4569dc
https://europepmc.org/articles/PMC8288064/
https://europepmc.org/articles/PMC8288064/